Year: 2010
Type: article
Abstract: Background
It is now well-known that a critical part of normal healing for cutaneous wounds is the formation of new blood vessels. As implantation of autologous bone marrow (BM)-derived Endothelial Progenitor Cells (EPC) into ischemic limbs has become a promising treatment for moderate to severe peripheral arterial occlusive disease (PAD), we have begun a Phase II randomized trial in Type 2 diabetes mellitus (T2DM). The goal of infusions is to promote neoangiogenesis, thereby increasing circulation, reducing symptoms, and facilitating wound healing. At first, we have studied EPC and gene expression profile (GEP) of peripheral blood, hypothesizing that it is possible to identify useful markers for the assessment of the severity of endothelial dysfunction.
Source: BMC Geriatrics
Language: English
Topic: Wound Healing and Treatments
Subfield: Rehabilitation
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
Funders: Ministero della Salute, Regione Calabria
OpenAlex ID: W2061189782
